[Federal Register Volume 59, Number 168 (Wednesday, August 31, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-21519]
[[Page Unknown]]
[Federal Register: August 31, 1994]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Calanolide Antiviral
Compounds, Compositions, and Uses Thereof
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH),
Department of Health and Human Services, is contemplating the grant of
an exclusive world-wide license to practice the invention embodied in
U.S. Patent Applications SN 07/861,249 and 08/065,618 both entitled
``Calanolide Antiviral Compounds, Compositions and Uses Thereof'' and
related foreign patent applications to MediChem Research, Inc. of
Lemont, IL. The patent rights in this invention have been assigned to
the United States of America.
The prospective exclusive license will be royalty-bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
It is anticipated that this license may be limited to the field of
treatment of AIDS. This prospective exclusive license may be granted
unless within 60 days from the date of this published notice, NIH
receives written evidence and argument that establishes that the grant
of the license would not be consistent with the requirements of 35
U.S.C. 209 and 37 CFR 404.7.
The patent applications describe the chemical structures of and
methods for isolating and purifying coumarins from an extract of the
tropical rain forest trees Calophyllum langerum and a related species
in the genus, Calophyllum teysmannii. This new class of compounds and
their analogs, also referred to as calanolides and costatolides
respectively, strongly inhibit HIV-1 replication and cytopathicity in
vitro. These compounds may have advantageous pharmacologic,
toxicologic, and/or antiviral properties, especially in the treatment
of AIDS.
ADDRESSES: Requests for a copy of this patent application, inquiries,
comments and other materials relating to the contemplated license
should be directed to: Steven M. Ferguson, Technology Licensing
Specialist, Office of Technology Transfer, National Institutes of
Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852.
Telephone: (301) 496-7735; Facsimile: (301) 402-0220; E-mail:
[email protected] Applications for a license filed in response
to this notice will be treated as objections to the grant of the
contemplated license. Only written comments and/or applications for a
license which are received by NIH within sixty (60) days of this notice
will be considered. A signed Confidential Disclosure Agreement will be
required to receive copies of the patent applications.
Dated: August 20, 1994.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 94-21519 Filed 8-30-94; 8:45 am]
BILLING CODE 4140-01-P
